Why has Pfizer stock floundered?
1 day ago · Analysts expect that Pfizer will report earnings of $7.23 per share in the current year and earnings of $5.69 per share in the next year, so the stock is trading at 9 forward P/E.
Should I buy Pfizer Inc. (PFE)?
Feb 08, 2022 · Pfizer stock has already declined by roughly 20% from the highs that were reached back in December, but it is not clear whether speculative traders will rush to buy the dip. If the market views...
Where will Pfizer be in 5 years?
Apr 20, 2022 · Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock. ... When earnings estimates for a company go up, the fair value for its stock goes up as well. ... INTC) stock is down 11% ...
Why is PFE dropping?
Dec 22, 2021 · Today's decline appears to be a by-product of the overall market rising after a pullback in recent days due to concerns about the spread of the coronavirus omicron variant. When COVID-19 fears...
The pharma stock is moving in the opposite direction of the overall market
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Key Points
Pfizer's shares fell as the overall market rose after a pullback in recent days related to omicron concerns.
What happened
Shares of Pfizer ( NYSE:PFE) were sinking 4.4% as of 11:18 a.m. ET on Tuesday. The big drugmaker didn't report any new developments. Today's decline appears to be a by-product of the overall market rising after a pullback in recent days due to concerns about the spread of the coronavirus omicron variant.
So what
The reality is that little has changed in the expectations about the impact of the omicron variant since Monday when Pfizer's shares rose while many stocks were dropping. As such, little has changed about Pfizer's prospects. Today's move is probably more noise than anything else.
Now what
Investors will definitely want to monitor how the efficacy of Pfizer's vaccine with a booster dose fares against the omicron variant. If the efficacy wanes, it could lead to new orders for the omicron-specific vaccine version that Pfizer and BioNTech are developing.
What happened
Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (NYSE: PFE) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were falling 7%. Moderna (NASDAQ: MRNA) stock was tumbling 5.4%. Novavax (NASDAQ: NVAX) was the biggest loser with its shares declining 8.1%.
So what
It's really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.
Now what
Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
NYSE: PFE
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NYSE: PFE
So why are these vaccine stocks tumbling today? Investors appear to be looking past the current surge in COVID-19 cases and expect a future where fewer vaccine doses are administered.
So what
Investors should always look forward. And the number of COVID-19 vaccine doses sold by Pfizer, BioNTech, and Moderna could very well decline significantly after 2022 (or perhaps 2023).
Now what
Cuba Gooding, Jr.'s character in the movie Jerry Maguire had a famous line that seems applicable for Pfizer, BioNTech, and Moderna: "Show me the money." The main thing for investors to watch with all three companies is the money -- in particular, supply deals for COVID-19 vaccines for beyond 2022.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Why is Pfizer down?
Another reason Pfizer has been down is that they've had some clinical setbacks. They really had high hopes for breast cancer drug Ibrance, and early breast cancer setting, and had a couple of clinical studies that didn't pan out so well, and so that's been another negative impact on the stock.
Why is Pfizer weighing down?
One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth, earnings growth, and that's been a big problem.
Is Pfizer still in clinical trial?
Investors are still waiting on data from Pfizer's ongoing clinical trial for its coronavirus vaccine candidate. A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector.
Does Pfizer have an answer?
In fact, it seems Pfizer doesn't have an answer yet. During the company's third-quarter earnings conference call, Bourla said: "I can say today that the data monitoring committee has not been unblinded to efficacy data nor has it conducted any interim efficacy analysis today.
When will Pfizer Biontech be released?
Last month, Pfizer announced that the latest batch of 200 million doses would be delivered between October of this year and April of 2022.
Is Shionogi a Pfizer?
Shionogi is months behind Pfizer and Merck, which have started later-stage tests of pills to treat Covid-19. Pfizer has said its twice-daily pill could be ready to hit the market as soon as this year. It is preparing to enroll more than 2,000 patients in a test of the antiviral pill combined with a booster antiviral drug against a placebo.
